Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study. Issue 4 (3rd April 2019)

• Record Type: Journal Article
• Authors: Sumon, Zarchi E.; Berenson, Charles S.; Sellick, John A.; Bulman, Zackery P.; Tsuji, Brian T.; Mergenhagen, Kari A.
• Is Part Of: Infectious diseases. Volume 51:Issue 4(2019)
• Page Start: 287
• Page End: 292
• Publication Date: 2019-04-03
• Subjects: Prosthetic valve endocarditis -- vancomycin-intermediate S. aureus -- time-kill study; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; 616.9
• DOI: 10.1080/23744235.2018.1533646
• Languages: English
• ISSNs: 2374-4235

Abstract

Abstract: Infectious complications following surgical valve replacements are extremely difficult to treat, often requiring prolonged antimicrobials therapy with or without surgery. Vancomycin-intermediate Staphylococcus aureus is an infrequent pathogen, with an estimated prevalence of less than 0.3%, but presents even greater challenges. We report a case of successful cure of daptomycin-non-susceptible and vancomycin-intermediate Staphylococcus aureus prosthetic valve endocarditis using an eight-week course of combination antimicrobial therapy. Using time-kill study, the combination of daptomycin plus ceftaroline and rifampin resulted in a greater than 4 log reduction of bacterial growth at 24 hours. This antimicrobial combination was used for a total of eight weeks with a successful outcome.